Trial Profile
A registration trial of CPI-444 in late-stage advanced refractory renal cancer patients.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2020
Price :
$35
*
At a glance
- Drugs Ciforadenant (Primary)
- Indications Renal cancer; Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- 29 Oct 2020 According to a Corvus Pharmaceuticals media release, the proposed pivotal trial will utilize the Company's Adenosine Gene Signature biomarker to select patients who may be most likely to benefit from treatment with ciforadenant plus atezolizumab.
- 05 Oct 2020 According to a Corvus Pharmaceuticals media release, Corvus is planning to meet with the U.S. Food & Drug Administration (FDA) in December 2020 to discuss the study design and plans for a pivotal ciforadenant study in advanced refractory renal cell cancer (RCC) using the Adenosine Gene Signature as a biomarker.
- 11 Nov 2017 According to a Corvus Pharmaceuticals media release, this trial is expected to begin in 2018.